Issue Date: January 14, 2013
Gilead, MacroGenics Join For Antibodies
Gilead Sciences and MacroGenics have entered into a licensing deal under which the companies will develop four unspecified therapies using MacroGenics’ Dual Affinity Re-Targeting (DART) antibody platform, which is a bispecific technology that allows a single recombinant molecule to target two different antigens. Under the agreement, Gilead will pay MacroGenics, based in Rockville, Md., up to $30 million in licensing fees and up to $85 million in clinical milestone payments . . .
To view the rest of this content, please log in with your ACS ID.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society